1
|
Risinskaya N, Kozhevnikova Y, Gavrilina O, Chabaeva J, Kotova E, Yushkova A, Isinova G, Zarubina K, Obukhova T, Kulikov S, Julhakyan H, Sudarikov A, Parovichnikova E. Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes (Basel) 2022; 13:genes13030398. [PMID: 35327952 PMCID: PMC8952291 DOI: 10.3390/genes13030398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/16/2022] [Accepted: 02/21/2022] [Indexed: 11/29/2022] Open
Abstract
Despite the introduction of new technologies in molecular diagnostics, one should not underestimate the traditional routine methods for studying tumor DNA. Here we present the evidence that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome. Tumor STR profiles of 87 adult patients with de novo Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 mixed phenotype acute leukemia (MPAL)) treated according to the “RALL-2016” regimen were analyzed. DNA of tumor cells was isolated from patient bone marrow samples taken at diagnosis. Control DNA samples were taken from the buccal swab or the blood of patients in complete remission. Overall survival (OS) analysis was used to assess the independent impact of the LOH as a risk factor. Of the 87 patients, 21 were found with LOH in various STR loci (24%). For B-ALL patients, LOH (except 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395). In contrast, for T-ALL patients, the OS hazard ratio was 0.59 (log-rank p-value 0.62). LOH in particular STR loci measured at the onset of the disease could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.
Collapse
Affiliation(s)
- Natalya Risinskaya
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Yana Kozhevnikova
- School of Medicine, Lomonosov Moscow State University, 27-1, Lomonosovsky Prospect, 119991 Moscow, Russia;
| | - Olga Gavrilina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Julia Chabaeva
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ekaterina Kotova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Anna Yushkova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Galina Isinova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ksenija Zarubina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Tatiana Obukhova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Sergey Kulikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Hunan Julhakyan
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Andrey Sudarikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
- Correspondence:
| | - Elena Parovichnikova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| |
Collapse
|
2
|
Galtseva IV, Zvonkov EE, Badmazhapova DS, Davydova Y, Kapranov N, Moiseeva TN, Al-Radi LS, Kovrigina AM, Obukhova TN, Julhakyan H, Danishyan KI, Sabirov KR, Kislitsyna M, Goryacheva S, Parovichnikova EN, Savchenko VG. Characteristics of immunological synapse in mature B-cell neoplasms. Int J Lab Hematol 2020; 42:e294-e297. [PMID: 32870581 DOI: 10.1111/ijlh.13326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 07/23/2020] [Accepted: 08/04/2020] [Indexed: 11/28/2022]
|
3
|
Petrova A, Chelysheva E, Shukhov O, Bykova A, Nemchenko I, Gusarova G, Tsyba N, Julhakyan H, Shuvaev V, Fominykh M, Martynkevich I, Ionova T, Turkina A. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. Clin Lymphoma Myeloma Leuk 2020; 20:267-271. [PMID: 32146103 DOI: 10.1016/j.clml.2019.12.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 12/26/2019] [Accepted: 12/30/2019] [Indexed: 01/01/2023]
Abstract
We aimed to characterize withdrawal syndrome (WS) and evaluate factors associated with its development in the prospective clinical study RU-SKI in patients with chronic myeloid leukemia with deep molecular response who discontinued tyrosine kinase inhibitor (TKI) therapy. In total, 98 adult patients with chronic myeloid leukemia chronic phase, TKI therapy ≥ 3 years, and deep molecular response (BCR-ABL ≤ 0.01%) ≥ 2 years were enrolled and observed without treatment. WS was defined as newly observed or worsening musculoskeletal pain after TKI cessation. WS symptoms were found in 41 (42%) of 98 patients with a median time of observation of 25 months (range, 12-42 months). WS grades 1 to 2 and grade 3 were observed in 39 (95%) and in 2 (5%) patients, respectively. The median duration of WS was 5 months (range, 1-25 months). WS was resolved in 37 (90%) patients. Anti-inflammatory therapy was used in 21 (51%) patients. Older age (P = .039) and longer TKI therapy (P = .001) were associated with WS. The 2-month landmark analysis found no association of WS development and the rate of molecular relapses. In total, 42% of the patients experienced WS after TKI therapy discontinuation in the RU-SKI study. Physicians should be warned about the possibility of WS development, and patients of older age and with longer TKI treatment need special attention.
Collapse
Affiliation(s)
- Anna Petrova
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Ekaterina Chelysheva
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Oleg Shukhov
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Anastasiya Bykova
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Irina Nemchenko
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Galina Gusarova
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Nikolay Tsyba
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| | - Hunan Julhakyan
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation.
| | - Vasiliy Shuvaev
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint-Petersburg, Russian Federation; City Clinical Hospital n.a. V.V. Veresaev of the Moscow Department of Healthcare, Moscow, Russian Federation
| | - Mikhail Fominykh
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint-Petersburg, Russian Federation; Academic Chair of Hospital Therapy, Saint-Petersburg State University, Saint-Petersburg, Russian Federation
| | - Irina Martynkevich
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint-Petersburg, Russian Federation
| | - Tatyana Ionova
- Chair of Quality of Life Unit, Saint-Petersburg State University Hospital, Saint Petersburg, Russian Federation; Quality of Life Monitoring Department, Multinational Center for Quality of Life Research, Saint Petersburg, Russian Federation
| | - Anna Turkina
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russian Federation
| |
Collapse
|
4
|
Biderman B, Julhakyan H, Koroleva D, Zvonkov E, Nikitin E, Sudarikov A. PB1874 STEREOTYPE ANTIGEN RECEPTORS IN B-CELL LYMPHOPROLIFERATIVE DISEASES. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000566000.58862.d5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|